You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

AMBIEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ambien patents expire, and what generic alternatives are available?

Ambien is a drug marketed by Sanofi Aventis Us and is included in two NDAs.

The generic ingredient in AMBIEN is zolpidem tartrate. There are thirty-three drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ambien

A generic version of AMBIEN was approved as zolpidem tartrate by ACME LABS on April 23rd, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AMBIEN?
  • What are the global sales for AMBIEN?
  • What is Average Wholesale Price for AMBIEN?
Drug patent expirations by year for AMBIEN
Drug Prices for AMBIEN

See drug prices for AMBIEN

Drug Sales Revenue Trends for AMBIEN

See drug sales revenues for AMBIEN

Recent Clinical Trials for AMBIEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institutes of Health (NIH)Phase 2
University of ArizonaPhase 4
University of VirginiaPhase 4

See all AMBIEN clinical trials

US Patents and Regulatory Information for AMBIEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us AMBIEN zolpidem tartrate TABLET;ORAL 019908-001 Dec 16, 1992 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-001 Sep 2, 2005 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us AMBIEN zolpidem tartrate TABLET;ORAL 019908-002 Dec 16, 1992 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-002 Sep 2, 2005 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AMBIEN

See the table below for patents covering AMBIEN around the world.

Country Patent Number Title Estimated Expiration
Japan S637545 ⤷  Sign Up
Finland 71143 ⤷  Sign Up
South Africa 8107297 ⤷  Sign Up
Austria 7393 ⤷  Sign Up
Israel 64091 ⤷  Sign Up
Finland 813288 ⤷  Sign Up
New Zealand 198722 N-SUBSTITUTED-2-(PHENYL OR NAPHTHYL)IMIDAZO(1,2-A)-PYRID-3-YLACETAMIDES ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AMBIEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2236132 C300714 Netherlands ⤷  Sign Up PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132 300714 Netherlands ⤷  Sign Up PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
2236132 122015000006 Germany ⤷  Sign Up PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2236132 92636 Luxembourg ⤷  Sign Up PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2236132 CA 2015 00004 Denmark ⤷  Sign Up PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.